The company expressly reserved all rights and remedies to pursue any and all claims against Organogenesis in the future, including those in the original complaint.
While MiMedx still maintains that Organogenesis “engaged in misconduct against MiMedx,” the company decided to spend its time and resources in protracted litigation with Organogenesis at this time. MiMedx will now focus on investigating Organogenesis’ activities against the company involving the Veterans Administration as well as other government agencies and MiMedx customers.
The company hopes to address all “improper conduct” by Organogenesis at one time.
More articles on orthopedic devices:
Double-digit growth for Precision Spine in 2014—5 key updates
SpineGuad gets FDA thumbs-up for PediGuard
K2M sets follow-on offering at $18.75 per share — 5 things to know
